1.26

3.70% 0.045

After Hours: 1.27 0.01 +0.79%

Pmv Pharmaceuticals Inc (PMVP)

Overview News Price History Option Chain Financials Discussions Forecast

Pmv Pharmaceuticals Inc stock is traded at $1.26, with a volume of 189.82K. It is up +3.70% in the last 24 hours and down -11.27% over the past month. PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

Previous Close:

$1.215

Open:

$1.23

24h Volume:

189.82K

Relative Volume:

0.54

Market Cap:

$67.20M

Revenue:

Net Income/Loss:

$-78.34M

P/E Ratio:

-0.8503

EPS:

-1.4819

Net Cash Flow:

$-75.02M

1W Performance:

+5.88%

1M Performance:

-11.27%

6M Performance:

+13.51%

1Y Performance:

-18.71%

1-Day Range:

$1.215

$1.285

1-Week Range:

$1.16

$1.33

52-Week Range:

$1.02

$1.88

Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile

Name

Pmv Pharmaceuticals Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(609) 642-6670

Address

400 ALEXANDER PARK DRIVE, PRINCETON

Employee

Twitter

Next Earnings Date

2026-08-20

Latest SEC Filings

PMVP's Discussions on Twitter

Compare PMVP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PMVP Pmv Pharmaceuticals Inc	1.26	67.20M	0	-78.34M	-75.02M	-1.4819
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-08-24	Upgrade	Oppenheimer	Perform → Outperform
May-13-24	Initiated	Craig Hallum	Buy
Apr-12-24	Initiated	Jefferies	Buy
Dec-27-23	Initiated	Ladenburg Thalmann	Buy
Mar-02-22	Upgrade	Oppenheimer	Perform → Outperform
Sep-22-21	Upgrade	Goldman	Neutral → Buy
Aug-19-21	Initiated	Oppenheimer	Perform
Aug-02-21	Initiated	Guggenheim	Buy
Jul-29-21	Initiated	H.C. Wainwright	Buy
Oct-20-20	Initiated	BofA Securities	Buy
Oct-20-20	Initiated	Cowen	Outperform
Oct-20-20	Initiated	Evercore ISI	Outperform
Oct-20-20	Initiated	Goldman	Neutral

View All

Pmv Pharmaceuticals Inc Stock (PMVP) Latest News

Aug 14, 2026

PMV Pharmaceuticals (NASDAQ:PMVP) Posts Earnings Results, Beats Expectations By $0.05 EPS - marketbeat.com

Aug 14, 2026

Pmv Pharmaceuticals Inc (NASDAQ: PMVP) Share Price, PMVP Stock News, PMVP Share Price & Updates - Kalkine

Aug 14, 2026

PMV Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet

Aug 14, 2026

Form 8K Pmv Pharmaceuticals Inc For: 14 August By Investing.com - Investing.com Nigeria

Aug 14, 2026

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times

Aug 14, 2026

PMV Pharma Reports $18.1 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 14, 2026

PMV Pharmaceuticals (PMVP) flags going-concern risk as rezatapopt advances toward NDA - Stock Titan

Aug 14, 2026

PMVP: Net loss narrowed, but liquidity concerns persist as rezatapopt advances toward NDA submission - TradingView

Aug 14, 2026

Ovarian cancer drug trial completes enrollment; PMV plans 2027 filing - Stock Titan

Aug 14, 2026

Aug 10, 2026